HS
HighVista Strategies Portfolio holdings
AUM
$272M
This Quarter Return
+14.9%
1 Year Return
+24.34%
3 Year Return
+176.43%
5 Year Return
+271.23%
10 Year Return
+682.63%
AUM
$272M
AUM Growth
+$272M
(+4.9%)
Cap. Flow
-$12.8M
Cap. Flow
% of AUM
-4.69%
Top 10 Holdings %
Top 10 Hldgs %
27.33%
Holding
177
New
29
Increased
50
Reduced
55
Closed
31
Top Buys
| 1 |
Viridian Therapeutics
VRDN
|
$4.25M |
| 2 |
Advanced Micro Devices
AMD
|
$2.19M |
| 3 |
Celldex Therapeutics
CLDX
|
$2.17M |
| 4 |
Ferguson
FERG
|
$2.15M |
| 5 |
Mineralys Therapeutics
MLYS
|
$2.03M |
Top Sells
| 1 |
Albertsons Companies
ACI
|
$4.15M |
| 2 |
GE Vernova
GEV
|
$3.07M |
| 3 |
SWTX
SpringWorks Therapeutics
SWTX
|
$3.03M |
| 4 |
Alphabet (Google) Class C
GOOG
|
$2.1M |
| 5 |
Bausch Health
BHC
|
$2.03M |
Sector Composition
| 1 | Healthcare | 37.62% |
| 2 | Technology | 22.09% |
| 3 | Industrials | 8.52% |
| 4 | Financials | 6.08% |
| 5 | Consumer Discretionary | 5.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
126
Ascendis Pharma
ASND
$12.1B
| $513K | 0.19% |
2,974
-3,098
| -51% | -$535K |
|
127
Trip.com Group
TCOM
$46.6B
| $496K | 0.18% |
8,456
-4,000
| -32% | -$235K |
|
128
Perspective Therapeutics
CATX
$251M
| $476K | 0.17% |
138,350
| – | – |
|
129
Tarsus Pharmaceuticals
TARS
$2.44B
| $473K | 0.17% |
+11,680
| New | +$473K |
|
130
89bio
ETNB
$1.37B
| $468K | 0.17% |
+47,633
| New | +$468K |
|
131
Nokia
NOK
$23.6B
| $433K | 0.16% |
+83,500
| New | +$433K |
|
132
Alcon
ALC
$38.9B
| $430K | 0.16% |
+6,123
| New | +$430K |
|
133
Alibaba
BABA
$325B
| $426K | 0.16% |
3,757
-3,700
| -50% | -$420K |
|
134
Pharvaris
PHVS
$1.41B
| $418K | 0.15% |
23,739
+971
| +4% | +$17.1K |
|
|
ABVX
135
Abivax
ABVX
$6.32B
| $391K | 0.14% |
51,156
+2,092
| +4% | +$16K |
|
136
Disc Medicine
IRON
$2.14B
| $357K | 0.13% |
6,733
+275
| +4% | +$14.6K |
|
137
NewAmsterdam Pharma
NAMS
$2.8B
| $349K | 0.13% |
+19,274
| New | +$349K |
|
138
Dianthus Therapeutics
DNTH
$781M
| $295K | 0.11% |
15,861
-15,526
| -49% | -$289K |
|
139
CG Oncology
CGON
$2.19B
| $269K | 0.1% |
10,328
-11,977
| -54% | -$311K |
|
140
Xencor
XNCR
$594M
| $262K | 0.1% |
33,304
+1,362
| +4% | +$10.7K |
|
141
Dyne Therapeutics
DYN
$1.92B
| $251K | 0.09% |
26,324
-52,096
| -66% | -$496K |
|
142
Cullinan Oncology
CGEM
$456M
| $240K | 0.09% |
31,893
| – | – |
|
143
Tyra Biosciences
TYRA
$657M
| $239K | 0.09% |
24,962
+1,021
| +4% | +$9.77K |
|
144
Wave Life Sciences
WVE
$1.27B
| $234K | 0.09% |
35,958
-17,416
| -33% | -$113K |
|
145
Geron
GERN
$893M
| $187K | 0.07% |
132,711
+5,427
| +4% | +$7.65K |
|
146
TAL Education Group
TAL
$6.34B
| $185K | 0.07% |
+18,100
| New | +$185K |
|
147
Zymeworks
ZYME
$1.07B
| – | – |
-41,607
| Closed | -$496K |
|
148
United Airlines
UAL
$34.4B
| – | – |
-20,200
| Closed | -$1.39M |
|
149
TSMC
TSM
$1.2T
| – | – |
-8,900
| Closed | -$1.48M |
|
|
SWTX
150
DELISTED
SpringWorks Therapeutics
SWTX
| – | – |
-68,758
| Closed | -$3.03M |
|